Phosphodiesterase inhibitors in inflammatory bowel disease

Expert Opinion on Investigational Drugs

Volumn 21, Issue 3, 2012, Pages 261-264

  Salari, Pooneh ^a   Abdollahi, Mohammad ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Inflammatory bowel disease; Phosphodiesterase inhibitors

Indexed keywords

CYCLIC GMP; DAXALIPRAM; GAMMA INTERFERON; INFLIXIMAB; NITRIC OXIDE; PHOSPHODIESTERASE INHIBITOR; PROSTAGLANDIN E2; REACTIVE OXYGEN METABOLITE; ROFLUMILAST; ROLIPRAM; SILDENAFIL; TETOMILAST; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ADHESION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; GASTROINTESTINAL TRACT; HUMAN; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; LEUKOCYTE; NONHUMAN; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; ULCERATIVE COLITIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; COLITIS, ULCERATIVE; CROHN DISEASE; DRUG SYNERGISM; HUMANS; OXIDANTS; PHOSPHODIESTERASE INHIBITORS;

EID: 84856854497     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2012.658915     Document Type: Review

References (14)

1. Rezaie A, Parker RD, Abdollahi M. Oxidative stress and pathogenesis of inflammatory bowel disease: an epiphenomenon or the cause? Dig Dis Sci 2007;52:2015-21 (Pubitemid 47246507)
2. Nikfar S, Mirfazaelian H, Abdollahi M. Efficacy and tolerability of immunoregulators and antibiotics in fistulizing Crohn's disease: a systematic review and meta-analysis of placebo-controlled trials. Curr Pharm Des 2010;16(33):3684-98
3. Hosseini-Tabatabaei A, Abdollahi M. Potassium channel openers and improvement of toxic stress: do they have role in the management of inflammatory bowel disease? Inflamm Allergy Drug Targets 2008;7(3):129-35
4. Salari P, Abdollahi M. Current opinion in the pharmaceutical management of irritable and inflammatory bowel diseases: role of ATP. Recent Pat Endocr Metabol Immun Drug Discov 2009;3(1):69-75
5. Khoshakhlagh P, Bahrololoumi-Shapourabadi M, Mohammadirad A, et al. Beneficial effect of phosphodiesterase-5 inhibitor in experimental inflammatory bowel disease; molecular evidence for involvement of oxidative stress. Toxicol Mech Methods 2007;17:281-8 (Pubitemid 46956946)
6. Salari-Sharif P, Abdollahi M. Phosphodiesterase 4 inhibitors in inflammatory bowel disease: a comprehensive review. Curr Pharm Des 2010;16:3661-7.
7. Salari P, Mojtahedzadeh M, Najafi A, et al. Comparison of the effect of aminophylline and low PEEP vs. high PEEP on EGF concentration in critically ill patients with ALI/ARDS. J Clin Pharm Ther 2005;30:139-44 (Pubitemid 41583608)
8. Rahimi R, Ghiasi S, Azimi H, et al. A review of the herbal phosphodiesterase inhibitors; Future perspective of new drugs. Cytokine 2010;49:123-9
9. Schreiber S, Keshavarzian A, Isaacs KL, et al. A randomized, placebo-controlled, phase II study of tetomilast in active ulcerative colitis. Gastroenterology 2007;132:76-86. (Pubitemid 46108758)
10. Keshavarzian A, Mutlu E, Guzman JP, et al. Phosphodiesterase 4 inhibitors and inflammatory bowel disease: emerging therapies in inflammatory bowel disease. Expert Opin Investig Drugs 2007;16(9):1489-506. (Pubitemid 47491417)
11. Giembycz MA, Smith SJ. Phosphodiesterase 7A: a new therapeutic target for alleviating chronic inflammation? Curr Pharm Des 2006;12:3207-20 (Pubitemid 44364133)
12. Kadoshima-Yamaoka K, Murakawa M, Goto M, et al. Effect of phosphodiesterase 7 inhibitor ASB16165 on development and function of cytotoxic T lymphocyte. Int Immunopharmacol 2009;9:97-102
13. Iseri SO, Ersoy Y, Ercan F, et al. The effect of sildenafil, a phosphodiesterase-5 inhibitor, on acetic acid-induced colonic inflammation in the rat. J Gastroenterol Hepatol 2009;24:1142-8
14. Ernst PB, Garrison JC, Thompson LF. Much Ado about adenosine: adenosine synthesis and function in regulatory T cell biology. J Immunol 2010;185:1993-8